This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00699751
First received: June 17, 2008
Last updated: April 27, 2016
Last verified: April 2016
Results First Received: June 29, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Hormone Refractory Prostate Cancer
Bone Metastases
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
Drug: Placebo
Drug: Best standard of care (BSoC)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects with progressive symptomatic hormone refractory prostate cancer (HRPC), with at least 2 skeletal metastases on bone scan and no known visceral metastases, could participate in the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects were to be randomized in a 2:1, a total of 921 subjects were enrolled in the study and were randomized to receive either Alpharadin [Radium-223 dichloride (Xofigo, BAY88-8223)] or placebo study treatment, which resulted in 614 subjects enrolled in the Alpharadin group and 307 enrolled in the placebo group.

Reporting Groups
  Description
Radium-223 Dichloride (Xofigo, BAY88-8223) Participants received BSoC plus radium223 50 kBq/kg body weight for 6 IV administrations separated by 4 weeks intervals.
Placebo Participants received BSoC plus isotonic saline for 6 IV administrations separated by 4 weeks intervals in double-blind phase; Participants received radium223 50 kBq/kg body weight for 6 intravenous administrations separated by 4 weeks intervals after unblinding to the end of study.

Participant Flow for 2 periods

Period 1:   Period 1: Without/Before Drug Switch
    Radium-223 Dichloride (Xofigo, BAY88-8223)   Placebo
STARTED   614   307 
Participants Received Treatment   600   301 
Entered 3-Year Follow-up Period   407 [1]   168 [1] 
Completed 3-Year Follow-up Period   49   12 
COMPLETED   389 [2]   145 [2] 
NOT COMPLETED   225   162 
Investigator Request                27                27 
Death                28                29 
Subject Request                43                23 
Unspecified                30                20 
Adverse Event                97                63 
[1] Participants were not required to complete all 6 injections to enter to 3-year follow-up period.
[2] Completed all 6 injections

Period 2:   Period 2:Switched From Placebo to Xofigo
    Radium-223 Dichloride (Xofigo, BAY88-8223)   Placebo
STARTED   0   26 [1] 
Participants Received Treatment   0   24 
Entered 3-Year Follow-up Period   0   15 
Completed 3-Year Follow-up Period   0   0 
COMPLETED   0   17 [2] 
NOT COMPLETED   0   9 
Adverse Event                0                4 
Investigator Request                0                1 
Completion page not expected                0                4 
[1] Participants in the placebo group switched to Xofigo treatment
[2] Completed all 6 injections



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Radium-223 Dichloride (Xofigo, BAY88-8223) Radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus BSoC.
Placebo Isotonic saline for 6 IV administrations separated by 4 weeks intervals plus BSoC.
Total Total of all reporting groups

Baseline Measures
   Radium-223 Dichloride (Xofigo, BAY88-8223)   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 614   307   921 
Age 
[Units: Years]
Mean (Standard Deviation)
 70.2  (8.10)   70.8  (7.87)   70.4  (8.03) 
Gender 
[Units: Participants]
     
Female   0   0   0 
Male   614   307   921 
Total Alkaline Phosphatase (ALP) [1] 
[Units: Participants]
     
< 220 U/L   348   169   517 
≥ 220 U/L   266   138   404 
[1] The total amount of ALP in the blood was determined at baseline.
Current use of bisphosphonates [1] 
[Units: Participants]
     
Yes   250   124   374 
No   364   183   547 
[1] Subjects may have been on bisphosphonate therapy during the study.
Any prior use of docetaxel 
[Units: Participants]
     
Yes   352   174   526 
No   262   133   395 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival   [ Time Frame: From randomization to death due to any cause until approximately 3 years after start of enrollment, the data was collected up to the second data analysis date (15 JUL 2011) ]

2.  Secondary:   Time to Total Alkaline Phosphatase (ALP) Progression   [ Time Frame: From randomization to first ALP progression until approximately 3 years after start of enrollment ]

3.  Secondary:   Percentage of Participants With Total ALP Response at Week 12   [ Time Frame: At Baseline and Week 12 ]

4.  Secondary:   Percentage of Participants With Total ALP Response at End of Treatment (EOT; Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)   [ Time Frame: At Baseline and End of Treatment (Week 24 or at the time the patient dies or discontinues treatment phase) ]

5.  Secondary:   Percentage of Participants With Total ALP Normalization at Week 12   [ Time Frame: At Baseline and Week 12 ]

6.  Secondary:   Percentage Change From Baseline in Total ALP at Week 12   [ Time Frame: At Baseline and Week 12 ]

7.  Secondary:   Maximum Percentage Decrease From Baseline in Total ALP up to Week 12   [ Time Frame: From baseline to Week 12 ]

8.  Secondary:   Percentage Change From Baseline in Total ALP at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)   [ Time Frame: At Baseline and End of Treatment (Week 24 or at the time the patient dies or discontinues treatment phase) ]

9.  Secondary:   Maximum Percentage Decrease From Baseline in Total ALP During the 24 Week Treatment   [ Time Frame: From baseline During the 24 Week Treatment ]

10.  Secondary:   Time to Prostate Specific Antigen (PSA) Progression   [ Time Frame: From randomization to first PSA progression until approximately 3 years after start of enrollment ]

11.  Secondary:   Percentage of Participants With PSA Response at Week 12   [ Time Frame: At Baseline and Week 12 ]

12.  Secondary:   Percentage of Participants With PSA Response at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)   [ Time Frame: At Baseline and End of Treatment (Week 24 or at the time the patient dies or discontinues treatment phase) ]

13.  Secondary:   Percentage Change From Baseline in PSA at Week 12   [ Time Frame: At Baseline and Week 12 ]

14.  Secondary:   Maximum Percentage Decrease From Baseline in PSA up to Week 12   [ Time Frame: From baseline up to Week 12 ]

15.  Secondary:   Percentage Change From Baseline in PSA at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)   [ Time Frame: At Baseline and End of Treatment (Week 24 or at the time the patient dies or discontinues treatment phase) ]

16.  Secondary:   Maximum Percentage Decrease From Baseline in PSA Response During the 24 Week Treatment Period   [ Time Frame: From baseline to End of Treatment (Week 24; 4 weeks post last injection) ]

17.  Secondary:   Time to First Skeletal Related Event (SRE)   [ Time Frame: From randomization to first first SRE until approximately 3 years after start of enrollment ]

18.  Secondary:   Time to Occurrence of First Use of External Beam Radiation Therapy (EBRT) to Relieve Skeletal Symptoms   [ Time Frame: From randomization to first EBRT until approximately 3 years after start of enrollment ]

19.  Secondary:   Time to Occurrence of First Use of Radioisotopes to Relieve Skeletal Symptoms   [ Time Frame: From randomization to first use of radioisotopes until approximately 3 years after start of enrollment ]

20.  Secondary:   Time to Occurrence of First New Symptomatic Pathological Bone Fractures, Vertebral and Non-vertebral   [ Time Frame: From randomization to occurrence of first new symptomatic pathological bone fractures until approximately 3 years after start of enrollment ]

21.  Secondary:   Time to Occurrence of First Tumor Related Orthopedic Surgical Intervention   [ Time Frame: From randomization to occurrence of first tumor related orthopedic surgical intervention until approximately 3 years after start of enrollment ]

22.  Secondary:   Time to Occurrence of First Spinal Cord Compression   [ Time Frame: From randomization to first spinal cord compression until approximately 3 years after start of enrollment ]

23.  Secondary:   Time to Occurrence of First Start of Any Other Anti-cancer Treatment   [ Time Frame: From randomization to first start of any other anti-cancer treatment until approximately 3 years after start of enrollment ]

24.  Secondary:   Time to Occurrence of First Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least 2 Points From Baseline   [ Time Frame: From randomization to first deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) until approximately 3 years after start of enrollment ]

25.  Other Pre-specified:   Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG PS) at Week 0.   [ Time Frame: Week 0 ]

26.  Other Pre-specified:   Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG PS) at Week 8.   [ Time Frame: Week 8 ]

27.  Other Pre-specified:   Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG PS) at Week 16.   [ Time Frame: Week 16 ]

28.  Other Pre-specified:   Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG PS) at Week 24.   [ Time Frame: Week 24 ]

29.  Other Pre-specified:   Absolute Scores for Functional Assessment of Cancer Therapy – Prostate (FACT-P) Trial Outcome Index (TOI)   [ Time Frame: Baseline, Week 16, Week 24, and Follow-up Visit 2 (Week 42) ]

30.  Other Pre-specified:   Changes From Baseline for FACT-P Trial Outcome Index (TOI) at Week 16, Week 24, and Follow-up Visit 2 (Week 42)   [ Time Frame: Baseline, Week 16, Week 24, and Follow-up Visit 2 (Week 42) ]

31.  Other Pre-specified:   Absolute Scores for Physical Well Being, Social/Family Well Being, Emotional Well Being, Functional Well Being, and the Prostate Cancer Subscale at Week 16   [ Time Frame: At Week 16 ]

32.  Other Pre-specified:   Absolute Scores for Physical Well Being, Social/Family Well Being, Emotional Well Being, Functional Well Being, and the Prostate Cancer Subscale at Week 24   [ Time Frame: At Week 24 ]

33.  Other Pre-specified:   Absolute Scores for Physical Well Being, Social/Family Well Being, Emotional Well Being, Functional Well Being, and the Prostate Cancer Subscale at Follow-up Visit 2 (Week 42)   [ Time Frame: At Follow-up Visit 2 (Week 42) ]

34.  Other Pre-specified:   Absolute Scores for FACT-P Total Score at Week 16, Week 24, and Follow-up Visit 2 (Week 42)   [ Time Frame: At Week 16, Week 24, and Follow-up Visit 2 (Week 42) ]

35.  Other Pre-specified:   Change From Baseline for FACT-P Total Score at Week 16, Week 24, and Follow-up Visit 2 (Week 42)   [ Time Frame: Baseline, Week 16, Week 24, and Follow-up Visit 2 (week 42) ]

36.  Other Pre-specified:   Absolute Scores for Functional Assessment of Cancer Therapy – General (FACT-G) Total Score at Week 16, Week 24, and Follow-up Visit 2 (Week 42)   [ Time Frame: At Week 16, Week 24, and Follow-up Visit 2 (Week 42) ]

37.  Other Pre-specified:   Change From Baseline for FACT-G Total Score at Week 16, Week 24, and Follow-up Visit 2 (Week 42)   [ Time Frame: Baseline, Week 16, Week 24, and Follow-up Visit 2 (Week 42) ]

38.  Other Pre-specified:   Number of Participants in the Euro Quality of Life (EQ-5D) Components for Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression at Week 16   [ Time Frame: Week 16 ]

39.  Other Pre-specified:   Number of Participants in the Euro Quality of Life (EQ-5D) Components for Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression at Week 24   [ Time Frame: Week 24 ]

40.  Other Pre-specified:   Number of Participants in the Euro Quality of Life (EQ-5D) Components for Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression at Follow-up Visit 8 (Week 139)   [ Time Frame: Follow-up Visit 8 (Week 139) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Therapeutic Area Head
Organization: BAYER
e-mail: clinical-trials-contact@bayerhealthcare.com


Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00699751     History of Changes
Other Study ID Numbers: 15245
BC1-06 ( Other Identifier: Algeta ASA )
2007-006195-11 ( EudraCT Number )
Study First Received: June 17, 2008
Results First Received: June 29, 2013
Last Updated: April 27, 2016